Beijing Genecradle Therapeutics Co., Ltd.
PrivateLast Round
Series A
Extension
Jun 12, 2025
Company Overview
Beijing Genecradle Therapeutics Co., Ltd. operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series A Extension round in June 2025.
Beijing Genecradle Therapeutics Co., Ltd. is a biotechnology company that develops gene therapy drugs and AAV vector delivery technologies for rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beijing Genecradle Therapeutics Co., Ltd. Comparables
Compare Beijing Genecradle Therapeutics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Frontera Therapeutics | 86% | |
| Belief BioMed Inc. | 86% | |
| Exegenesis Bio | 84% |
For institutional investors. Book with your work email.
Beijing Genecradle Therapeutics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jun 12, 2025 | ||||
| Series A | Dec 29, 2023 | ||||
| VC Round | Jun 1, 2023 | ||||
| Angel | Jul 7, 2022 | ||||
| Seed | Jan 5, 2022 |
For institutional investors. Book with your work email.
Beijing Genecradle Therapeutics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Genesis Capital | Angel |
| 深流资本 | Seed |
| Co-Win Ventures | Angel |
| Tianjin Venture Capital Management Co., Ltd. | Series A Extension |
| 华创资本 | Seed |
| Danlu Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 29, 2023
Raised Series A round led by Danlu Capital.
- Jun 1, 2023
$14M raised in a VC Round.
For institutional investors. Book with your work email.
Beijing Genecradle Therapeutics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beijing Genecradle Therapeutics Co., Ltd.'s valuation, stock price, and market status.
Is Beijing Genecradle Therapeutics Co., Ltd. a public or private company?
Beijing Genecradle Therapeutics Co., Ltd. is a private company.
What is the current stock price of Beijing Genecradle Therapeutics Co., Ltd.?
Beijing Genecradle Therapeutics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Beijing Genecradle Therapeutics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beijing Genecradle Therapeutics Co., Ltd. worth (valuation)?
Valuation information for Beijing Genecradle Therapeutics Co., Ltd. is not publicly available.
Can I buy Beijing Genecradle Therapeutics Co., Ltd. stock?
Beijing Genecradle Therapeutics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beijing Genecradle Therapeutics Co., Ltd.'s last funding round?
Beijing Genecradle Therapeutics Co., Ltd.'s most recent funding round was Series A Extension on June 12, 2025.
Who are the main investors in Beijing Genecradle Therapeutics Co., Ltd.?
Key investors in Beijing Genecradle Therapeutics Co., Ltd. include Tianjin Venture Capital Management Co., Ltd., 华创资本, Danlu Capital.
Will Beijing Genecradle Therapeutics Co., Ltd. IPO soon?
No public IPO plans have been announced for Beijing Genecradle Therapeutics Co., Ltd..
How can I track Beijing Genecradle Therapeutics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Beijing Genecradle Therapeutics Co., Ltd.'s shares on secondary markets.